RU2418793C2 - Соединение оксазола и фармацевтическая композиция - Google Patents
Соединение оксазола и фармацевтическая композиция Download PDFInfo
- Publication number
- RU2418793C2 RU2418793C2 RU2008123839/04A RU2008123839A RU2418793C2 RU 2418793 C2 RU2418793 C2 RU 2418793C2 RU 2008123839/04 A RU2008123839/04 A RU 2008123839/04A RU 2008123839 A RU2008123839 A RU 2008123839A RU 2418793 C2 RU2418793 C2 RU 2418793C2
- Authority
- RU
- Russia
- Prior art keywords
- group
- groups
- oxazol
- substituted
- phenyl
- Prior art date
Links
- 0 CNc1c[o]c(*)n1 Chemical compound CNc1c[o]c(*)n1 0.000 description 2
- CKVGCMRMJXEWDD-UHFFFAOYSA-N CCOc(c(OCC)c1)ccc1-c1nc(CCC(N2CCCC2)=O)c[o]1 Chemical compound CCOc(c(OCC)c1)ccc1-c1nc(CCC(N2CCCC2)=O)c[o]1 CKVGCMRMJXEWDD-UHFFFAOYSA-N 0.000 description 1
- JOVNWRRNBZMSKU-UHFFFAOYSA-N CCOc(c(OCC)c1)ccc1-c1nc(CCC(c2cccc(C)c2OCC)=O)c[o]1 Chemical compound CCOc(c(OCC)c1)ccc1-c1nc(CCC(c2cccc(C)c2OCC)=O)c[o]1 JOVNWRRNBZMSKU-UHFFFAOYSA-N 0.000 description 1
- FDOLLALDDDFPED-UHFFFAOYSA-N CCOc(ccc(-c1nc(C(NCC(c2ccccc2)=O)=O)c[o]1)c1)c1OCC Chemical compound CCOc(ccc(-c1nc(C(NCC(c2ccccc2)=O)=O)c[o]1)c1)c1OCC FDOLLALDDDFPED-UHFFFAOYSA-N 0.000 description 1
- IJPNCEMWWLRSAV-UHFFFAOYSA-N CCOc(ccc(-c1nc(C(NCCN2CCCC2)=O)c[o]1)c1)c1OCC Chemical compound CCOc(ccc(-c1nc(C(NCCN2CCCC2)=O)c[o]1)c1)c1OCC IJPNCEMWWLRSAV-UHFFFAOYSA-N 0.000 description 1
- YLSNBCYQECJSHL-UHFFFAOYSA-N CCOc(ccc(-c1nc(CCC(N2CCCC2)=O)c[o]1)c1)c1OC Chemical compound CCOc(ccc(-c1nc(CCC(N2CCCC2)=O)c[o]1)c1)c1OC YLSNBCYQECJSHL-UHFFFAOYSA-N 0.000 description 1
- HQULDVLKGXWCCB-UHFFFAOYSA-N COCOc(cccc1)c1C(CCc1c[o]c(-c(cc2)cc(OCc3ccccc3)c2OC)n1)=O Chemical compound COCOc(cccc1)c1C(CCc1c[o]c(-c(cc2)cc(OCc3ccccc3)c2OC)n1)=O HQULDVLKGXWCCB-UHFFFAOYSA-N 0.000 description 1
- PGFNREJNJKEWKL-UHFFFAOYSA-N FC(Oc(c(OC(F)F)c1)ccc1-c1nc(CCl)c[o]1)F Chemical compound FC(Oc(c(OC(F)F)c1)ccc1-c1nc(CCl)c[o]1)F PGFNREJNJKEWKL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/04—Phosphoric diester hydrolases (3.1.4)
- C12Y301/04012—Sphingomyelin phosphodiesterase (3.1.4.12)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005330590 | 2005-11-15 | ||
| JP2005-330590 | 2005-11-15 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2008123839A RU2008123839A (ru) | 2009-12-27 |
| RU2418793C2 true RU2418793C2 (ru) | 2011-05-20 |
Family
ID=37879936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008123839/04A RU2418793C2 (ru) | 2005-11-15 | 2006-11-14 | Соединение оксазола и фармацевтическая композиция |
Country Status (22)
| Country | Link |
|---|---|
| US (9) | USRE46792E1 (https=) |
| EP (1) | EP1954684B1 (https=) |
| JP (1) | JP5305914B2 (https=) |
| KR (1) | KR101439557B1 (https=) |
| CN (1) | CN101309912B (https=) |
| AR (3) | AR057891A1 (https=) |
| AU (1) | AU2006316079B2 (https=) |
| BR (1) | BRPI0618589B8 (https=) |
| CA (1) | CA2627541C (https=) |
| CY (1) | CY1115302T1 (https=) |
| DK (1) | DK1954684T3 (https=) |
| ES (1) | ES2483992T3 (https=) |
| IL (1) | IL191008A (https=) |
| MY (1) | MY153720A (https=) |
| NO (1) | NO341440B1 (https=) |
| PL (1) | PL1954684T3 (https=) |
| PT (1) | PT1954684E (https=) |
| RU (1) | RU2418793C2 (https=) |
| SI (1) | SI1954684T1 (https=) |
| TW (1) | TWI330639B (https=) |
| WO (1) | WO2007058338A2 (https=) |
| ZA (1) | ZA200803758B (https=) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4986927B2 (ja) * | 2007-05-14 | 2012-07-25 | 大塚製薬株式会社 | 医薬 |
| US9029408B2 (en) | 2008-06-16 | 2015-05-12 | Gtx, Inc. | Compounds for treatment of cancer |
| MX2010014066A (es) | 2008-06-16 | 2011-06-01 | Univ Tennessee Res Foundation | Compuestos para el tratamiento del cancer. |
| US9447049B2 (en) | 2010-03-01 | 2016-09-20 | University Of Tennessee Research Foundation | Compounds for treatment of cancer |
| US8822513B2 (en) | 2010-03-01 | 2014-09-02 | Gtx, Inc. | Compounds for treatment of cancer |
| GB2465890A (en) * | 2008-12-05 | 2010-06-09 | Scynexis Inc | 2-Arylazole derivatives as antiprotozoal agents |
| JP5879273B2 (ja) | 2010-03-01 | 2016-03-08 | ジーティーエックス・インコーポレイテッド | 癌を処置するための化合物 |
| EP2542089B1 (en) | 2010-03-05 | 2017-01-18 | Karyopharm Therapeutics, Inc. | Nuclear transport modulators and uses thereof |
| KR101713453B1 (ko) * | 2010-03-12 | 2017-03-07 | 오메로스 코포레이션 | Pde10 억제제 및 관련 조성물 및 방법 |
| EP2665362B1 (en) | 2011-01-17 | 2016-03-30 | Karyopharm Therapeutics, Inc. | Olefin containing nuclear transport modulators and uses thereof |
| JP6006794B2 (ja) | 2011-07-29 | 2016-10-12 | カリオファーム セラピューティクス，インコーポレイテッド | 核内輸送調節因子およびその使用 |
| EP4234545A3 (en) | 2011-07-29 | 2023-09-06 | Karyopharm Therapeutics Inc. | Hydrazide containing nuclear transport modulators and uses thereof |
| US8809372B2 (en) | 2011-09-30 | 2014-08-19 | Asana Biosciences, Llc | Pyridine derivatives |
| US9199975B2 (en) | 2011-09-30 | 2015-12-01 | Asana Biosciences, Llc | Biaryl imidazole derivatives for regulating CYP17 |
| CN104080770A (zh) | 2011-11-09 | 2014-10-01 | 迈兰实验室有限公司 | 用于制备罗氟司特的改进方法 |
| WO2013170068A2 (en) | 2012-05-09 | 2013-11-14 | Karyopharm Therapeutics, Inc. | Nuclear transport modulators and uses thereof |
| EP2890686B1 (en) | 2012-08-30 | 2017-01-04 | Otsuka Pharmaceutical Co., Ltd. | Method for producing oxazole compound |
| EP2968278B8 (en) | 2013-03-15 | 2019-05-22 | Karyopharm Therapeutics Inc. | Methods of promoting wound healing using crm1 inhibitors |
| ME03421B (me) | 2013-06-21 | 2020-01-20 | Karyopharm Therapeutics Inc | 1,2,4-triazoli kao modulatori nuklearnog transporta i njihova upotreba |
| CN105085428B (zh) * | 2014-04-25 | 2019-03-22 | 广东东阳光药业有限公司 | 芳杂环类衍生物及其在药物上的应用 |
| NZ630803A (en) | 2014-04-28 | 2016-03-31 | Omeros Corp | Optically active pde10 inhibitor |
| NZ716494A (en) | 2014-04-28 | 2017-07-28 | Omeros Corp | Processes and intermediates for the preparation of a pde10 inhibitor |
| KR102608259B1 (ko) | 2014-08-15 | 2023-11-29 | 카리오팜 쎄라퓨틱스, 인코포레이티드 | 셀리넥소의 다형태 |
| TWI689497B (zh) * | 2014-09-04 | 2020-04-01 | 南北兄弟藥業投資有限公司 | 芳雜環類衍生物及其在藥物中的應用 |
| KR20170139074A (ko) | 2015-04-24 | 2017-12-18 | 오메로스 코포레이션 | Pde10 억제제 및 관련 조성물 및 방법 |
| CN106188027B (zh) * | 2015-09-02 | 2020-10-20 | 广东东阳光药业有限公司 | 芳杂环类衍生物及其在药物中的应用 |
| WO2017079678A1 (en) | 2015-11-04 | 2017-05-11 | Omeros Corporation | Solid state forms of a pde10 inhibitor |
| TWI726027B (zh) | 2015-12-28 | 2021-05-01 | 日商大塚製藥股份有限公司 | 軟膏 |
| CN106279138B (zh) * | 2015-12-29 | 2019-03-01 | 广东东阳光药业有限公司 | 芳杂环类衍生物及其在药物中的应用 |
| EP3397634A1 (en) | 2015-12-31 | 2018-11-07 | Karyopharm Therapeutics, Inc. | Nuclear transport modulators and uses thereof |
| US10526295B2 (en) | 2015-12-31 | 2020-01-07 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
| US11602530B2 (en) | 2016-11-28 | 2023-03-14 | Biogen Ma Inc. | CRM1 inhibitors for treating epilepsy |
| PL3774745T3 (pl) * | 2018-04-04 | 2024-08-19 | Otsuka Pharmaceutical Co., Ltd. | Kryształ cząsteczki oksazolu |
| CN116194451B (zh) * | 2020-11-27 | 2025-07-11 | 瑞石生物医药有限公司 | 芳基或杂芳基取代五元芳杂环化合物及其用途 |
| CN112425610A (zh) * | 2021-01-22 | 2021-03-02 | 深圳市洛奇机电科技有限公司 | 一种防治君子兰叶斑病的农药悬浮剂的制备系统及其应用 |
| TW202400154A (zh) | 2022-03-25 | 2024-01-01 | 日商大塚製藥股份有限公司 | 創傷治療用組合物 |
| CN115785014B (zh) * | 2022-12-27 | 2025-01-24 | 瑞石生物医药有限公司 | 四唑衍生物及其用途 |
| GB202306663D0 (en) | 2023-05-05 | 2023-06-21 | Union Therapeutics As | Combination therapy |
| JP7712737B1 (ja) | 2024-05-29 | 2025-07-24 | 大塚製薬株式会社 | オキサゾール化合物含有組成物 |
| CN119798183B (zh) * | 2024-12-19 | 2026-03-24 | 上海药坦药物研究开发有限公司 | 一种噁唑类化合物的制备方法 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996000218A1 (en) * | 1994-06-24 | 1996-01-04 | Euro-Celtique, S.A. | Compounds for and method of inhibiting phosphodiesterase iv |
| WO1998008830A1 (de) * | 1996-08-26 | 1998-03-05 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Thiazol-derivate als selektive inhibitoren der pde-iv |
| US5814651A (en) * | 1992-12-02 | 1998-09-29 | Pfizer Inc. | Catechol diethers as selective PDEIV inhibitors |
| RU2004105925A (ru) * | 2001-07-27 | 2005-07-10 | Байер Фармасьютикалс Корпорейшн (US) | Производные индануксусной кислоты и их применение в качестве фармацевтических агентов, промежуточные продукты и способ получения |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4735961A (en) | 1984-05-07 | 1988-04-05 | Merck & Co., Inc. | Oxazoles and thiazoles containing an aminohydroxypropoxyphenyl moiety |
| MX15171A (es) * | 1988-03-08 | 1993-05-01 | Pfizer | Derivados de tiazolidinodiona hipoglicemicos |
| US20020169173A1 (en) | 1993-11-08 | 2002-11-14 | Smithkline Beecham Corporation | Oxazoles for treating cytokine mediated diseases |
| AUPO156596A0 (en) | 1996-08-09 | 1996-09-05 | University Of Sydney, The | Synthetic polynucleotides |
| DE19632549A1 (de) | 1996-08-13 | 1998-02-19 | Merck Patent Gmbh | Arylalkanoylpyridazine |
| DE69722258T2 (de) | 1996-10-07 | 2004-03-18 | Eli Lilly And Co., Indianapolis | Neue verbindungen nutlich als neuroschützende mittel |
| US6020339A (en) | 1997-10-03 | 2000-02-01 | Merck & Co., Inc. | Aryl furan derivatives as PDE IV inhibitors |
| JP4518587B2 (ja) | 1998-03-09 | 2010-08-04 | 興和創薬株式会社 | ２−フェニルモルホリン誘導体 |
| IL161317A0 (en) | 2001-10-16 | 2004-09-27 | Memory Pharm Corp | 4-(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidone derivatives as pde-4 inhibitors for the treatment of neurological syndromes |
| US7259175B2 (en) | 2002-02-25 | 2007-08-21 | Eli Lilly And Company | Peroxisome proliferator activated receptor modulators |
| JP2004203871A (ja) * | 2002-12-13 | 2004-07-22 | Yamanouchi Pharmaceut Co Ltd | 医薬組成物 |
| TW200505913A (en) | 2003-03-28 | 2005-02-16 | Hoffmann La Roche | Novel oxazole derivatives, their manufacture and use as pharmaceutical agents |
| AU2005243384A1 (en) | 2004-05-17 | 2005-11-24 | Otsuka Pharmaceutical Co., Ltd. | Thiazole compound and use thereof |
| CA2575081C (en) | 2004-07-26 | 2013-05-07 | Eli Lilly And Company | Oxazole derivatives as histamine h3 receptor agents, preparation and therapeutic uses |
| DE102004051277A1 (de) | 2004-10-21 | 2006-04-27 | Merck Patent Gmbh | Heterocyclische Carbonylverbindungen |
| CA2602336A1 (en) * | 2005-03-31 | 2006-10-05 | Ucb Pharma S.A. | Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses |
-
2006
- 2006-11-14 PL PL06823467T patent/PL1954684T3/pl unknown
- 2006-11-14 KR KR1020087014483A patent/KR101439557B1/ko active Active
- 2006-11-14 PT PT68234673T patent/PT1954684E/pt unknown
- 2006-11-14 SI SI200631792T patent/SI1954684T1/sl unknown
- 2006-11-14 WO PCT/JP2006/323066 patent/WO2007058338A2/en not_active Ceased
- 2006-11-14 ES ES06823467.3T patent/ES2483992T3/es active Active
- 2006-11-14 AU AU2006316079A patent/AU2006316079B2/en active Active
- 2006-11-14 AR ARP060104973A patent/AR057891A1/es active IP Right Grant
- 2006-11-14 DK DK06823467.3T patent/DK1954684T3/da active
- 2006-11-14 CA CA2627541A patent/CA2627541C/en active Active
- 2006-11-14 ZA ZA200803758A patent/ZA200803758B/xx unknown
- 2006-11-14 BR BRPI0618589A patent/BRPI0618589B8/pt active IP Right Grant
- 2006-11-14 MY MYPI20081379A patent/MY153720A/en unknown
- 2006-11-14 TW TW095142068A patent/TWI330639B/zh active
- 2006-11-14 RU RU2008123839/04A patent/RU2418793C2/ru active
- 2006-11-14 CN CN200680042484XA patent/CN101309912B/zh active Active
- 2006-11-14 JP JP2008539670A patent/JP5305914B2/ja active Active
- 2006-11-14 EP EP06823467.3A patent/EP1954684B1/en active Active
- 2006-11-14 US US15/623,249 patent/USRE46792E1/en active Active
- 2006-11-14 US US12/090,951 patent/US8637559B2/en not_active Ceased
-
2008
- 2008-04-23 NO NO20081930A patent/NO341440B1/no unknown
- 2008-04-27 IL IL191008A patent/IL191008A/en active IP Right Grant
-
2013
- 2013-12-12 US US14/104,871 patent/US20140100226A1/en not_active Abandoned
-
2014
- 2014-07-01 CY CY20141100485T patent/CY1115302T1/el unknown
-
2017
- 2017-04-11 US US15/485,203 patent/US20170216260A1/en not_active Abandoned
- 2017-07-10 AR ARP170101904A patent/AR109006A2/es unknown
- 2017-07-10 AR ARP170101905A patent/AR109007A2/es unknown
-
2018
- 2018-11-01 US US16/178,517 patent/US20190070151A1/en not_active Abandoned
-
2019
- 2019-11-12 US US16/681,360 patent/US20200078340A1/en not_active Abandoned
-
2022
- 2022-02-24 US US17/679,659 patent/US20220265613A1/en not_active Abandoned
-
2024
- 2024-01-05 US US18/405,633 patent/US20240148699A1/en not_active Abandoned
-
2025
- 2025-12-17 US US19/422,682 patent/US20260108497A1/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5814651A (en) * | 1992-12-02 | 1998-09-29 | Pfizer Inc. | Catechol diethers as selective PDEIV inhibitors |
| WO1996000218A1 (en) * | 1994-06-24 | 1996-01-04 | Euro-Celtique, S.A. | Compounds for and method of inhibiting phosphodiesterase iv |
| WO1998008830A1 (de) * | 1996-08-26 | 1998-03-05 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Thiazol-derivate als selektive inhibitoren der pde-iv |
| RU2004105925A (ru) * | 2001-07-27 | 2005-07-10 | Байер Фармасьютикалс Корпорейшн (US) | Производные индануксусной кислоты и их применение в качестве фармацевтических агентов, промежуточные продукты и способ получения |
Non-Patent Citations (1)
| Title |
|---|
| MALAMAS M.S. et al. Azole Phenoxy Hydroxyureas as Selective and Orally Active Inhibitors of 5-Lipoxygenase. Jounal of Medicinal Chemistry. Vol.39, №1, 1996, 237-245. * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2418793C2 (ru) | Соединение оксазола и фармацевтическая композиция | |
| ES2457521T3 (es) | Derivados de 1,2,3-triazol para uso como inhibidores de estearoil-coA desaturasa | |
| EP1513812B1 (en) | Substituted indoles | |
| AU717699B2 (en) | Chemical compounds | |
| JP4986927B2 (ja) | 医薬 | |
| WO2011078370A1 (ja) | 新規パラバン酸誘導体及びそれらを有効成分とする医薬 | |
| US9567304B2 (en) | Quinazolinedione derivative | |
| HUP0300857A2 (hu) | Peroxiszóma proliferátor aktivált agonisták | |
| HK1121162B (zh) | 恶唑化合物和药物组合物 | |
| RS58539B1 (sr) | Nova jedinjenja kao inhibitori diacilglicerin aciltransferaze | |
| HK1160467B (en) | 1, 2, 3-triazole derivatives for use as stearoyl-coa desaturase inhibitors |